ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report)'s share price crossed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $48.88 and traded as low as $44.01. ProShares Ultra Nasdaq Biotechnology shares last traded at $46.00, with a volume of 6,354 shares.
ProShares Ultra Nasdaq Biotechnology Trading Up 1.3 %
The company has a market cap of $51.11 million, a P/E ratio of 21.19 and a beta of 1.63. The business's 50 day simple moving average is $48.46 and its 200 day simple moving average is $53.81.
ProShares Ultra Nasdaq Biotechnology Cuts Dividend
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 1st. Stockholders of record on Wednesday, March 26th were given a dividend of $0.1309 per share. The ex-dividend date was Wednesday, March 26th. This represents a $0.52 annualized dividend and a dividend yield of 1.13%.
Institutional Investors Weigh In On ProShares Ultra Nasdaq Biotechnology
A number of institutional investors have recently bought and sold shares of BIB. Jane Street Group LLC grew its position in shares of ProShares Ultra Nasdaq Biotechnology by 8.4% during the third quarter. Jane Street Group LLC now owns 4,803 shares of the exchange traded fund's stock worth $306,000 after purchasing an additional 374 shares in the last quarter. Crowley Wealth Management Inc. purchased a new stake in ProShares Ultra Nasdaq Biotechnology during the 4th quarter valued at approximately $51,000. Tower Research Capital LLC TRC raised its position in shares of ProShares Ultra Nasdaq Biotechnology by 31.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,326 shares of the exchange traded fund's stock valued at $270,000 after buying an additional 1,266 shares during the last quarter. Finally, IMC Chicago LLC purchased a new position in shares of ProShares Ultra Nasdaq Biotechnology in the first quarter worth $1,080,000.
ProShares Ultra Nasdaq Biotechnology Company Profile
(
Get Free Report)
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
Featured Articles
Before you consider ProShares Ultra Nasdaq Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProShares Ultra Nasdaq Biotechnology wasn't on the list.
While ProShares Ultra Nasdaq Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
